Business, energy, technology, markets and global industry news from Business News Today

EyeBio

PharmaDeviceNews EyeBio
Pharma & Biotech

Can Merck’s remigromig compete with anti-VEGF treatments after BRUNELLO results?

Merck's remigromig met BRUNELLO's vision endpoint, but higher retinal complication rates complicate its potential in diabetic macular edema.

Read More
Merck & Co.’s remigromig has met its pivotal diabetic macular edema efficacy endpoint after the company acquired EyeBio in a deal valued at up to $3 billion. Representative image.
Pharma & Biotech

Merck’s $3bn EyeBio bet clears first pivotal test as remigromig matches Lucentis

Merck & Co.’s remigromig matched ranibizumab on vision improvement in a pivotal diabetic macular edema trial, validating a novel Wnt-targeting approach while higher rates of proliferative diabetic retinopathy and vitreous hemorrhage leave an important safety question unresolved.

Read More
Ingenia Therapeutics’ dual Prix Galien USA and Korea nominations add visibility to the newly listed biotech as attention turns to its TIE2-based vascular therapeutics pipeline, including MK-8748 and IGT-303. Representative image.
Pharma & Biotech

Ingenia Therapeutics has two Prix Galien nominations, but its real test begins after the KOSDAQ IPO

Ingenia Therapeutics gains dual Prix Galien nominations as its KOSDAQ debut puts MK-8748, IGT-303 and the broader TIE2 pipeline under scrutiny.

Read More